Novartis halts Mid-Stage trial for rare lung disease treatment
NCT ID NCT05135000
Summary
This study tested whether adding an experimental drug called LTP001 to standard treatments could help people with pulmonary arterial hypertension, a serious lung and heart condition. About 47 participants took either LTP001 or a placebo pill daily for 24 weeks while continuing their usual medications. Researchers measured changes in heart pressure, walking distance, and quality of life to see if the drug showed enough promise for further development.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical Univ of South Carolina
Charleston, South Carolina, 29425, United States
-
Novartis Investigative Site
Caba, Buenos Aires, C1025ABI, Argentina
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Amsterdam, 1081 HV, Netherlands
-
Novartis Investigative Site
Krakow, 31 202, Poland
-
Novartis Investigative Site
Lodz, 91-347, Poland
-
Novartis Investigative Site
Wroclaw, 50-556, Poland
-
Novartis Investigative Site
Málaga, Andalusia, 29010, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Sheffield, South Yorkshire, S10 2JF, United Kingdom
-
Novartis Investigative Site
London, SW3 6PH, United Kingdom
-
Pulmonary Associates PA
Mesa, Arizona, 85206, United States
Conditions
Explore the condition pages connected to this study.